BIOTRANS

BIOTRANS, founded in 2018, is the first technology enterprise in China dedicated to the development and application of RNA editing omics technologies. The company is committed to solving the long-standing challenge of high-throughput, standardized detection technology in the clinical translation of RNA editing—a key post-transcriptional regulatory mechanism—providing systematic solutions for disease mechanism exploration, novel biomarker discovery, and drug target development.